⌘K

Login Start Free

Home/Filings/4/0000950170-24-141676

4//SEC Filing

Satvat Ali J. 4

Accession 0000950170-24-141676

CIK 0001743881other

View on SEC.gov Company Profile

Filed

Dec 30, 7:00 PM ET

Accepted

Dec 31, 5:52 PM ET

Size

13.5 KB

Accession

0000950170-24-141676

Insider Transaction Report

Form 4

Period: 2024-12-30

BridgeBio Pharma, Inc.BBIO

Director

Transactions

Exercise/Conversion
Common Stock
2024-12-30$16.68/sh+39,851$664,715→ 119,553 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-12-30−39,851→ 0 total
Exercise: $16.68Exp: 2029-06-12→ Common Stock (39,851 underlying)
Exercise/Conversion
Common Stock
2024-12-30$26.21/sh+39,851$1,044,495→ 159,404 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-12-30−39,851→ 0 total
Exercise: $26.21Exp: 2030-05-27→ Common Stock (39,851 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-12-30−79,702→ 0 total
Exercise: $10.99Exp: 2028-07-01→ Common Stock (79,702 underlying)
Exercise/Conversion
Common Stock
2024-12-30$10.99/sh+79,702$875,925→ 79,702 total

Footnotes (1)

[F1]The stock option was fully vested and exercisable on the date of issuance by the Issuer as of January 26, 2021.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother

Related Parties

1

filerCIK 0001621788

Filing Metadata

Form type: 4
Filed: Dec 30, 7:00 PM ET
Accepted: Dec 31, 5:52 PM ET
Size: 13.5 KB

View on SEC.gov